Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6276)
All Articles published online
|
Publishing Process of This Article
|
May 14, 2013 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19(18): 2793-2798 [PMID: 23687416 DOI: 10.3748/wjg.v19.i18.2793] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i18/2793.htm |
| Number | Citing Articles |
| 1 |
Ya Wen, Yi Xiang Zheng, De Ming Tan. A Comprehensive Long-Term Prognosis of Chronic Hepatitis C Patients With Antiviral Therapy; A Meta-Analysis of Studies From 2008 to 2014. Hepatitis Monthly 2015; 15(5) doi: 10.5812/hepatmon.15(5)2015.27181
|
| 2 |
Nobuhisa Akamatsu, Yasuhiko Sugawara, Norihiro Kokudo. Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. Expert Review of Anti-infective Therapy 2015; 13(11): 1307 doi: 10.1586/14787210.2015.1091724
|
| 3 |
Martin Pehrsson, Tina Manon‐Jensen, Shu Sun, Ida F. Villesen, Helena Castañé, Jorge Joven, Keyur Patel, Zachary Goodman, Mette J. Nielsen, Anne‐Christine Bay‐Jensen, Diana J. Leeming, Joachim H. Mortensen, Morten A. Karsdal. An MMP‐degraded and cross‐linked fragment of type III collagen as a non‐invasive biomarker of hepatic fibrosis resolution. Liver International 2022; 42(7): 1605 doi: 10.1111/liv.15270
|
| 4 |
Hyun Jung Lee, Jong Eun Yeon, Eileen L. Yoon, Sang Jun Suh, Keunhee Kang, Hae Rim Kim, Seong Hee Kang, Yang Jae Yoo, Jihye Je, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun. Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Interferon-Alpha: Risk of Cirrhosis and Hepatocellular Carcinoma in a Single Center over 10 Years. Intervirology 2015; 58(1): 14 doi: 10.1159/000369206
|
| 5 |
Farina M Hanif, Zain Majid, Nasir Hassan Luck, Abbas Ali Tasneem, Syed Muddasir Laeeq, Muhammed Mubarak. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World Journal of Hepatology 2022; 14(4): 647-669 doi: 10.4254/wjh.v14.i4.647
|
| 6 |
Christoph R Werner, Carolin Franz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer, Christoph P Berg. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. Virology Journal 2015; 12(1) doi: 10.1186/s12985-015-0261-0
|
| 7 |
Peter Hayes, John Plevris. Paper Alert. European Journal of Gastroenterology & Hepatology 2019; 31(10): 1295 doi: 10.1097/MEG.0000000000001512
|
| 8 |
Lingyao Du, Hong Tang. miRNA antagonism and direct-acting antivirals: could this be a novel combination treatment against HCV?. Future Virology 2016; 11(12): 753 doi: 10.2217/fvl-2016-0109
|
| 9 |
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Nicola Coppola, Guglielmo Borgia. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 2014; 12(10): 1179 doi: 10.1586/14787210.2014.945432
|
| 10 |
Maria Guarino, Anna Sessa, Valentina Cossiga, Federica Morando, Nicola Caporaso, Filomena Morisco, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World Journal of Gastroenterology 2018; 24(24): 2582-2595 doi: 10.3748/wjg.v24.i24.2582
|
| 11 |
Yuan-Ji Ma, Ling-Yao Du, Li-Bo Yan, Juan Liao, Xing Cheng, Wu-Wei Xie, Hong Tang. Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin. Hepatobiliary & Pancreatic Diseases International 2021; 20(2): 137 doi: 10.1016/j.hbpd.2020.02.004
|
| 12 |
Ahmed Nagaty, Ekram W. Abd El-Wahab, Tatsuo Kanda. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLOS ONE 2017; 12(10): e0184654 doi: 10.1371/journal.pone.0184654
|
| 13 |
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Emanuela Zappulo, Giuseppe Castaldo, Guglielmo Borgia. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opinion on Investigational Drugs 2014; 23(5): 719 doi: 10.1517/13543784.2014.902049
|
| 14 |
Antonio Craxì, Carlo Federico Perno, Mauro Viganò, Francesca Ceccherini-Silberstein, Salvatore Petta, Alessio Aghemo, Alfredo Alberti, Pietro Andreone, Massimo Andreoni, Stefano Bonora, Maurizia Rossana Brunetto, Savino Bruno, Nicola Caporaso, Antonio Chirianni, Alessia Ciancio, Elisabetta Degasperi, Giovanni Di Perri, Stefano Fagiuoli, Carlo Ferrari, Giovanni Battista Gaeta, Adriano Pellicelli, Massimo Puoti, Giovanni Raimondo, Gloria Taliani, Erica Villa, Anna Linda Zignego. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016; 48(9): 995 doi: 10.1016/j.dld.2016.06.004
|
| 15 |
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62(3): 932 doi: 10.1002/hep.27950
|
| 16 |
Sebastian Bernuth, Eray Yagmur, Detlef Schuppan, Martin F. Sprinzl, Anca Zimmermann, Arno Schad, Jens M. Kittner, Veronika Weyer, Johanna Knapstein, Jörn M. Schattenberg, Marcus A. Wörns, Peter R. Galle, Tim Zimmermann. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Digestive and Liver Disease 2016; 48(3): 291 doi: 10.1016/j.dld.2015.09.015
|
| 17 |
Nikita Chadha, Alan Turner, Richard K. Sterling. Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR. Journal of Viral Hepatitis 2023; 30(1): 73 doi: 10.1111/jvh.13763
|
| 18 |
Luca Rinaldi, Maria Guarino, Alessandro Perrella, Pia Clara Pafundi, Giovanna Valente, Luca Fontanella, Riccardo Nevola, Barbara Guerrera, Natalina Iuliano, Michele Imparato, Alessio Trabucco, Ferdinando Carlo Sasso, Filomena Morisco, Antonio Ascione, Guido Piai, Luigi Elio Adinolfi. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. Digestive Diseases and Sciences 2019; 64(10): 3013 doi: 10.1007/s10620-019-05604-8
|
| 19 |
Ahmed Nagaty, Sherine H A Helmy, Ekram W Abd El-Wahab. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt. Transactions of The Royal Society of Tropical Medicine and Hygiene 2020; 114(3): 200 doi: 10.1093/trstmh/trz079
|
| 20 |
Longteng Ma, Jiluo Liu, Wei Wang, Fan Yang, Ping Li, Shiliang Cai, Xinyu Zhou, Xi Chen, Xun Zhuang, Hongwei Zhang, Guangwen Cao. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncology 2020; 16(11): 675 doi: 10.2217/fon-2019-0845
|
| 21 |
Fanpu Ji, Zhifang Cai, Hong Deng. Relapse of hepatitis C in three immunocompetent patients achieved a sustained virological response following interferon-based antiviral therapy. Journal of Clinical Virology 2013; 58(3): 590 doi: 10.1016/j.jcv.2013.08.026
|
| 22 |
Ivan Gentile, Nicola Coppola, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs 2014; 23(9): 1211 doi: 10.1517/13543784.2014.921680
|
| 23 |
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Guglielmo Borgia. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Review of Anti-infective Therapy 2014; 12(7): 775 doi: 10.1586/14787210.2014.920254
|
| 24 |
A. Olveira, L. Domínguez, J. Troya, A. Arias, F. Pulido, P. Ryan, L. M. Benítez, J. González‐García, M. L. Montes. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct‐acting antivirals. Journal of Viral Hepatitis 2018; 25(7): 818 doi: 10.1111/jvh.12883
|
| 25 |
Nicola Coppola, Stefania De Pascalis, Mariantonietta Pisaturo, Laurenza Paradiso, Margherita Macera, Nicolina Capoluongo, Loredana Alessio, Maria Stanzione, Caterina Sagnelli, Carmine Minichini, Evangelista Sagnelli. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. Journal of Clinical Virology 2013; 58(4): 748 doi: 10.1016/j.jcv.2013.09.014
|
| 26 |
Sara Cuesta-Sancho, Mercedes Márquez-Coello, Francisco Illanes-Álvarez, Denisse Márquez-Ruiz, Ana Arizcorreta, Fátima Galán-Sánchez, Natalia Montiel, Manuel Rodriguez-Iglesias, José-Antonio Girón-González. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World Journal of Hepatology 2022; 14(1): 62-79 doi: 10.4254/wjh.v14.i1.62
|
| 27 |
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. Expert Review of Anti-infective Therapy 2014; 12(7): 763 doi: 10.1586/14787210.2014.929497
|
| 28 |
Scott J. Johnson, Hélène Parisé, Suchin Virabhak, Ivana Filipovic, Jennifer C. Samp, Derek Misurski. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. Journal of Medical Economics 2016; 19(10): 983 doi: 10.1080/13696998.2016.1189920
|
| 29 |
Imran Shahid, Qaiser Jabeen. Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives. 2023; : 175 doi: 10.2174/9789815123432123010010
|
| 30 |
Adriaan J van der Meer. Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease?. Expert Review of Gastroenterology & Hepatology 2015; 9(5): 559 doi: 10.1586/17474124.2015.1001366
|
| 31 |
Ivan Gentile, Alberto E. Maraolo, Massimo Niola, Vincenzo Graziano, Guglielmo Borgia, Mariano Paternoster. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016; 10(11): 1227 doi: 10.1080/17474124.2016.1234375
|
| 32 |
Christoph R Werner, Julia M Schwarz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer, Christoph P Berg. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World Journal of Gastroenterology 2016; 22(35): 8050-8059 doi: 10.3748/wjg.v22.i35.8050
|
| 33 |
Nicola Coppola, Ivan Gentile, Giuseppe Pasquale, Antonio Riccardo Buonomo, Nicolina Capoluongo, Maria D’Armiento, Guglielmo Borgia, Evangelista Sagnelli. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Annals of Hepatology 2014; 13(1): 20 doi: 10.1016/S1665-2681(19)30900-7
|
| 34 |
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Giuseppe Castaldo, Guglielmo Borgia. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opinion on Investigational Drugs 2014; 23(4): 561 doi: 10.1517/13543784.2014.892581
|
| 35 |
K. R. Dudina, P. A. Belyy, I. V. Maev, N. Kh. Safiullina, E. A. Klimova, S. A. Shutko, O. O. Znoyko, N. D. Yushchuk. Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2023; 32(5): 31 doi: 10.22416/1382-4376-2022-32-5-31-42
|
| 36 |
O. Tronina, K. Ślubowska, N. Mikołajczyk-Korniak, E. Komuda-Leszek, R. Wieczorek-Godlewska, B. Łągiewska, M. Pacholczyk, W. Lisik, M. Kosieradzki, M. Durlik. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Transplantation Proceedings 2017; 49(6): 1409 doi: 10.1016/j.transproceed.2017.01.077
|
| 37 |
Keol Lee, Dong Hyun Sinn, Geum-Youn Gwak, Hyun Chin Cho, Sin-Ho Jung, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut and Liver 2016; 10(5): 796 doi: 10.5009/gnl15368
|
| 38 |
Chiara Rosso, Gian Paolo Caviglia, Michela Ciruolo, Alessia Ciancio, Ramy Younes, Antonella Olivero, Chiara Giordanino, Giulia Troshina, Maria Lorena Abate, Mario Rizzetto, Rinaldo Pellicano, Giorgio M. Saracco, Elisabetta Bugianesi, Antonina Smedile. Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. Minerva Medica 2019; 110(5) doi: 10.23736/S0026-4806.19.06108-1
|
| 39 |
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Guglielmo Borgia. Beclabuvir for the treatment of hepatitis C. Expert Opinion on Investigational Drugs 2015; 24(8): 1111 doi: 10.1517/13543784.2015.1059820
|
| 40 |
Ariel Bardach, Akram Hernández-Vásquez, Alfredo Palacios, María Calderón, Natalie Soto, Dario Balan, Federico Augustovski. Epidemiology, Use of resources, and Costs of Medical Management of Hepatitis C in Argentina, Colombia, Uruguay, and Venezuela. Value in Health Regional Issues 2019; 20: 180 doi: 10.1016/j.vhri.2019.06.004
|
| 41 |
Peng Huang, Yan Wang, Ming Yue, Zhijun Ge, Xueshan Xia, Andre J. Jeyarajan, Jacinta A. Holmes, Rongbin Yu, Chuanwu Zhu, Sheng Yang, Wenyu Lin, Raymond T. Chung. The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver International 2021; 41(10): 2341 doi: 10.1111/liv.14976
|
| 42 |
Horng-Maw Chen, Tsung-Hsueh Lu, Kun-Chia Chang, Kuan-Ying Lee, Ching-Ming Cheng. Opioid users with comorbid hepatitis C spent more time in agonist therapy: A 6-year observational study in Taiwan. Addictive Behaviors 2017; 72: 133 doi: 10.1016/j.addbeh.2017.03.028
|
| 43 |
Ira M. Jacobson, Joseph K. Lim, Michael W. Fried. American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology 2017; 152(6): 1578 doi: 10.1053/j.gastro.2017.03.018
|
| 44 |
Ivan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opinion on Drug Discovery 2015; 10(12): 1363 doi: 10.1517/17460441.2015.1094051
|
| 45 |
Ragesh Babu Thandassery, Saad Al Kaabi, Madiha E. Soofi, Benjamin Tharian, Rajvir Singh. Noninvasive serum models to predict significant liver related events in chronic hepatitis C. Hepatology International 2017; 11(4): 401 doi: 10.1007/s12072-017-9800-7
|
| 46 |
Maissa El-Raziky, Marwa Khairy, Ahmed Fouad, Ahmed Salama, Aisha Elsharkawy, Omnia Tantawy. Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens. Journal of Interferon & Cytokine Research 2018; 38(3): 129 doi: 10.1089/jir.2017.0137
|
| 47 |
Rahul Mahapatra, Jack Fuhrer. HIV and GI Tract Complications. Clinical Gastroenterology 2019; : 91 doi: 10.1007/978-3-030-13377-1_5
|
| 48 |
M. Guarino, F. Morisco, M. R. Valvano, A. M. Ippolito, M. Librandi, N. Andriulli, M. Greco, A. Amoruso, A. Iacobellis, G. Niro, N. Caporaso, A. Andriulli. Systematic review: interferon‐free regimens for patients with HCV‐related Child C cirrhosis. Alimentary Pharmacology & Therapeutics 2017; 45(9): 1193 doi: 10.1111/apt.14017
|
| 49 |
Ivan Gentile, Antonio Riccardo Buonomo, Guglielmo Borgia. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 2014; 12(9): 1033 doi: 10.1586/14787210.2014.940898
|
| 50 |
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Riccardo Scotto, Guglielmo Borgia. Asunaprevir for hepatitis C: a safety evaluation. Expert Opinion on Drug Safety 2015; 14(10): 1631 doi: 10.1517/14740338.2015.1084287
|
| 51 |
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Discontinued drugs in 2012 – 2013: hepatitis C virus infection. Expert Opinion on Investigational Drugs 2015; 24(2): 239 doi: 10.1517/13543784.2015.982274
|
| 52 |
Hye Won Lee, Young Eun Chon, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kyu Sik Jung, Young Nyun Park, Kwang-Hyub Han. Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. Gut and Liver 2016; 10(3) doi: 10.5009/gnl15021
|